Malignant Ovarian Germ Cell Tumors in Pediatric Age Group: A Clinicopathological Study over 21 Years in Eastern Rajasthan (India)

Rajendra Kumar Tanwar¹, *, Bharti Saxena², Shankar Lal Mohanpuria², Harsh Goyal¹, Laxmi Agarwal³, Madhu Saxena⁴, Man Mohan Agarwal⁵

¹Department of Radiation Oncology, Government Medical College, Kota, Rajasthan University of Health Sciences, Jaipur, Rajasthan, India
²Department of Obstetrics and Gynaecology, Government Medical College, Kota, Rajasthan University of Health Sciences, Jaipur, Rajasthan, India
³Department of Pathology, Pushpadi Cancer Care Centre, Kota, Rajasthan, India
⁴Department of Anaesthesiology, Government Medical College, Kota, Rajasthan University of Health Sciences, Jaipur, Rajasthan, India
⁵Department of Surgical Oncology, Pushpadi Cancer Care Centre, Kota, Rajasthan, India

Email address:
rtanwar@rediffmail.com (R. K. Tanwar), bharti.saxena.kota@gmail.com (B. Saxena), Dr.Mohanpuria@gmail.com (S. L. Mohanpuria), drharsh222@gmail.com (H. Goyal), drlaxmiagarwal@gmail.com (L. Agarwal), rktanwar@rediffmail.com (M. Saxena), mag.cancer@gmail.com (M. M. Agarwal)

*Corresponding author

To cite this article:
Rajendra Kumar Tanwar, Bharti Saxena, Shankar Lal Mohanpuria, Harsh Goyal, Laxmi Agarwal, Madhu Saxena, Man Mohan Agarwal. Malignant Ovarian Germ Cell Tumors in Pediatric Age Group: A Clinicopathological Study over 21 Years in Eastern Rajasthan (India). Cancer Research Journal. Vol. 8, No. 4, 2020, pp. 57-61. doi: 10.11648/j.crj.20200804.11

Received: August 18, 2020; Accepted: September 3, 2020; Published: October 27, 2020

Abstract: Background: The aim of this study is to analyze the clinicopathological features, diagnosis and treatment outcome of rare cases of malignant ovarian germ cell tumors in a government tertiary care hospital centre keeping fertility preservation surgery as a goal in young girls below 21 years of age. Methods: This is a retrospective study comprising of 24 patients diagnosed to have malignant ovarian germ cell tumors who attend the department of Radiation Oncology from 1998 to 2019 over 21 years period. The patients were evaluated on the basis of their age, obstetric history, investigations, and serum tumor markers estimation. All patients were staged according to FIGO, ECOG score were noted. Unilateral Salpingo oophorectomy (USO) with or without staging laparotomy surgery was done and BEP chemotherapy regimen was given. Response to treatment was evaluated by regular clinical examination, radiological and tumor marker studies. Results: In our study 17 patients were in FIGO stage III and 6 patients were in stage IV. The size of the primary tumor was 10-20 cm. in 15 patients. The various histology observed was-dysgerminoma -8, malignant teratoma-5, mixed germ cell tumor-5, yolk sac tumor-4 and embryonal carcinoma in 2 patients. Eighteen patients underwent fertility preservation surgery i.e. USO - 15, and 3 patients underwent USO with staging laparotomy. In 14 patients 3-4 cycles of adjuvant chemotherapy (BEP regimen) was administered and all of them achieved complete remission. Conclusion: Malignant ovarian germ cell tumors carries excellent prognosis in spite of advanced stage disease. Patients should be referred to oncology centre and to be operated by gynecologic oncologist/ oncosurgeon. Adjuvant chemotherapy should be given to achieve complete remission.

Keywords: Germ Cell Tumor Ovary, Fertility Preserving Surgery, Neo-adjuvant Chemotherapy, BEP Regimen

1. Introduction

The pediatric age group includes adolescence i.e. up to 21 years now days. The malignant germ cell tumors of the ovary account for 2-3% of all ovarian cancers and occur mostly in their early twenties. More over 10-30% of ovarian neoplasm’s operated during childhood or adolescent girls are malignant. [1] Significant improvement in the management.
of malignant ovarian germ cell tumors (MOGCT) has been achieved during past three decades because of major development in the area of proper histological diagnosis, clinical staging, tumor marker estimation, immunohistochemistry, facilities of oncosurgery and adjuvant chemotherapy. [2] Among MOGCT, the incidence of immature teratoma are most common 42-48%, followed by dysgerminoma 24-27%, mixed germ cell tumors (GCT) 14-20% and yolk sac tumor (YST) formally known as endodermal sinus tumor in 11-12%. [3, 4] The pure embryonal carcinoma and choriocarcinoma are rarely seen in ovary rather they are seen as a component of mixed GCT of ovary. The mixed GCT of the ovary contains two or more different types of germ cell neoplasms. The most frequent combination has been dysgerminoma and YST. [5] A good number of patients with MOGCTs are long term survivors and suffer minimum morbidity from treatment. Fertility preservation surgical procedures enable young women to preserve their reproducing potential. [2, 3] The better results are achieved due to team approach management including gynecologic oncology, medical oncology, pathology and radiology. Nogales FF et al described para neoplastic syndrome i.e. autoimmune encephalitis due to antibodies against the N-methyl-D-aspartate receptor has been reported most frequent autoimmune disorder associated with ovarian teratoma. [6]

2. Methods

A retrospective review of medical records of 24 patients of MOGCTs in pediatric age group from September 1998 to November 2019 over 21 years who attended department of Radiation Oncology in our Institution was performed. The patients were operated in department of Obstetrics and Gynecology of our Institute as well as at other hospitals, were referred for further treatment. The records of these patients were evaluated for written informed consent, age, obstetric history, treatment received before coming to this institute. General physical examination, pelvico-abdominal examination, routine hematological, serological tests including tumor markers viz. alpha fetoprotein (AFP), beta human chorionic gonadotrophin (β-hCG), lactic dehydrogenase (LDH), CA-125, skigram of the chest, USG of the abdomen and pelvis were done. Computerized tomography of the abdomen, pelvis and chest were done to evaluate clinical staging of the disease (Table 1). Eastern Cooperative Oncology Group (ECOG) Performance Score was noted.

All patients were evaluated for surgery. Neo-adjuvant chemotherapy was given in patients who were found to have extensive disease to make the tumor operable. BEP chemotherapy regimen as follows.

- **Inj. Bleomycin 20mg/M² I.V. Day 1, 8, 15**
- **Inj. Etoposide 100 mg/M² I.V. Day 1-5**
- **Inj. Cisplatin 20mg/M² I.V. D1-5**

Every three weekly for 3-4 cycles with injection Filgrastim 5 mcg/kg S. C. day 6.

Treatment related toxicities were observed and managed appropriately.

Remission was considered when clinical, radiological and tumor marker levels were within normal limits. Patients were followed every monthly till one year with investigations every 3 monthly, then follow up every 3 monthly during 2nd year and every 6 monthly subsequently.

### Table 1. Figo* staging of ovarian germ cell tumors.

| Stage | Description |
|-------|-------------|
| I     | Tumor limited to ovaries (one or both). |
| IA    | Tumor limited to one ovary, no ascites, intact capsule. |
| IB    | Tumor limited to both ovaries, no ascites, intact capsule. |
| IC    | Tumor either Stage IA or IB, but with ascites present containing malignant cells or with ovarian capsule involvement or rupture or with positive peritoneal washings. |
| II    | Tumor involving one or both ovaries with extension to the pelvis. |
| IIA   | Extension to uterus or fallopian tubes. |
| IIB   | Involvement of both ovaries with pelvic extension. |
| IIC   | Tumor either Stage IIA or IIB, but with ascites present containing malignant cells or with ovarian capsule involvement or rupture or with positive peritoneal washings. |
| III   | Tumor involving one or both ovaries with tumor implants outside the pelvis or with positive retro peritoneal or inguinal lymph nodes. |
| IIIA  | Superficial liver metastases qualify as stage III |
| IIIB  | Tumor limited to the pelvis with negative nodes but with microscopic seeding of the abdominal peritoneal surface. |
| IIIC  | Negative nodes, tumor implants in the abdominal cavity less than 2 cm. |
| IV    | Positive nodes, tumor implants in the abdominal cavity more than 2 cm. |
|      | Distant metastasis present |

* FIGO: International Federation of Gynecologists and Obstetricians

3. Results

### 3.1. Clinical Profile

A large number of our patients presented with advanced stage of disease due to a variety of reasons. Majority of these patients were illiterate and belonging to poor economic backgrounds. They reach the oncology treatment centre quite late. The age ranges from 9-20 years (Mean age 16.17) (Table 2). In two patients the Hemoglobin was found below 10 Gm% at the time of presentation. One patient has extensive loco regional disease involving vulva, perineal mass, palpable inguinal lymph nodes, infiltration of vagina and rectum with retention of urine therefore supra pubic
cystostomy was done. All patients were presented with abdominal distension and pain. In 9 patients the tumor was found arising from left ovary and in 8 patients from right ovary where as in 7 patients, the laterality of the tumor could not be ascertained due to advanced disease. In 15 (62.5%) patients, the size of primary tumor was between 10-20 cm. Ascites was present in 10 patients. Four patients showed hydronephrotic changes radiologically however serum renal functions were found within normal range. We observed peritoneal carcinomatosis in 1, pleural effusion -2, hepatic metastasis -2, pulmonary metastasis -1 and associated tubercular lymphadenopathy of para aortic lymph nodes in one patient. The ECOG performance score revealed Score I in 5 patients, Score II -8, Score III in 6 and Score IV in 5 patients.

3.2. Treatment Given

Only one patient had stage I disease, while remaining patients were presented with advanced stage disease - Stage III - 17 (70.83%) and stage IV - 6 (25.0%). Eighteen patients underwent surgery - Unilateral salphingo oophorectomy (USO) -15 and staging laparotomy in 3 patients. Six patients were found to be inoperable so diagnosis was made by FNAC only. The final histopathological diagnosis arrived was Dysgerminoma in 8 (33.33%), Malignant Teratoma - 5 (20.83%) and Mixed Germ cell Tumor - 5 (20.83%), Yok Sac Tumor - 4 (16.66%) and Embryonal Carcinoma - 2 (8.33%). All patients were planned BEP chemotherapy regimen. Four patients (16.66%) completed 3 cycles and 10 patients (41.66%) completed 4 cycles of BEP chemotherapy.

During treatment, 2 patients developed neutropenia grade IV after administration of 1st cycle chemotherapy, were recovered after treatment. All fourteen patients who completed post operative chemotherapy achieved complete remission and cured. One patient died of intestinal obstruction. In this study, only one patient was married before treatment, achieved complete remission and conceived 2 years after treatment and delivered a healthy child.

| Clinical Characteristics | Number of patients | Percentage |
|--------------------------|--------------------|------------|
| Age (Years) | Range 9-20 Years, Mean Age 16.17 |
| Laterality of Tumor | Left side | 9 | 37.50 |
| | Right Side | 8 | 33.33 |
| | Side could not be ascertained | 7 | 29.16 |
| Primary Tumor Size | Less than 5 cm. | 1 | 4.16 |
| | 5-10 cm | 3 | 12.50 |
| | 10-15 cm | 10 | 41.66 |
| | 15-20 cm | 5 | 20.83 |
| | More than 20 cm | 5 | 20.83 |
| Tissue Diagnosis by | FNAC | 6 | 25.00 |
| Biopsy | 18 | 75.00 |
| FIGO Staging | Stage I | 1 | 4.16 |
| | Stage III | 17 | 70.83 |
| | Stage IV | 6 | 25.00 |
| Surgical treatment | USO | 15 | 62.50 |
| | Staging Laparotomy | 3 | 12.50 |
| | Inoperable | 6 | 25.00 |
| Radiation Therapy | Palliative | 1 | 4.16 |
| Histopathology | Dysgerminoma | 8 | 33.33 |
| | Malignant Teratoma | 5 | 20.83 |
| | Mixed Germ cell Tumor | 5 | 20.83 |
| | Yok Sac Tumor | 4 | 16.66 |
| | Embryonal Carcinoma | 2 | 8.33 |
| Performance Score | ECOG -I | 5 | 20.83 |
| | ECOG -II | 8 | 33.33 |
| | ECOG -III | 6 | 25.00 |
| | ECOG - IV | 5 | 20.83 |
| Number of BEP Cycles given | 1 | 7 | 29.16 |
| | 2 | 2 | 8.33 |
| | 3 | 4 | 16.66 |
| | 4 | 10 | 41.66 |

| Histopathology | AFP | B-hCG |
|----------------|-----|-------|
| Dysgerminoma | - | ± |
| Yok Sac Tumor (EST) | + | - |
| Malignant Teratoma | ± | - |
| Mixed Germ cell Tumor | ± | ± |
| Choriocarcinoma | - | + |
| Embryonal Carcinoma | ± | + |
4. Discussion

The MOGCTs are derived from primordial germ cells which undergo defective mitosis. Karyotypic abnormalities are common and include aneuploidy or chromosomal rearrangements. [7] The MOGCT occurs in girls and young women with a median age between 16-20 years depending on histological subtypes. [8] The majority of patients presents with abdominal pain associated with palpable pelvic/abdominal mass. Other symptoms are acute abdominal distension, fever or vaginal bleeding. A few patients exhibit isosexual precocity (precocious puberty) because of β-hCG production by tumor cells. [9] These markers (if initially raised) are helpful in diagnosis, response to treatment and detection of subclinical recurrent disease in follow up. (Table 3) Interestingly serum CA-125 level can also be nonspecifically elevated in patients with ovarian GCTs. [10] In the present study dysgerminoma was most common histological subtype followed by malignant teratoma, mixed GCT, yok sac tumor and embryonal carcinoma. This is similar to other reports from India. [11, 12] In the USA, there was a different distribution of various histological subtypes reported. Smith et al (2006) analyzed SEER data of 30 years (1973-2002) and identified 1262 patients of ovarian GCT, out of which 38.5% were teratomas and 32.8% dysgerminomas. [13] The peak incidence of GCT in their series was 15-19 years age group. [13], whereas in our series the median age was 16.17 years. Most patients were operated by gynecologists and do not undergo comprehensive staging. In such cases, postoperative CT scan of the abdomen and pelvis are recommended. If histopathology and available information from first surgery clearly indicates ovarian GCT, re exploration is not advisable. [2] These tumors are highly sensitive to chemotherapy therefore systemic chemotherapy should be instituted. [2] The re exploration for comprehensive staging is advisable in patients to confirm FIGO stage I, grade 1 immature teratoma or dysgerminoma who would undergo surveillance and forego chemotherapy in the event of negative comprehensive staging. [4, 14]

Unlike epithelial ovarian cancers, germ cell tumors are amenable to fertility preservation and hence conservative surgery should be standard of care whenever possible. Gershenson [15], Perrin [16], Ezzat [17], Brewer [18] and Lakshmanan [11] in their series described fertility preservation surgery and delivered healthy babies (Table 4). There is very little Indian data available. [11] In our study only one patient was married before treatment who became mother. This number may be less as all patients except one were unmarried prior to diagnosis and due to social taboo continue to remain unmarried long after completing treatment. The most common effective chemotherapy regimen is BEP. [14] The chemotherapy dose reduction or delay in administration is not recommended even in the setting of neutropenia to achieve maximum tumor control. For residual or recurrent disease high dose chemotherapy or additional chemotherapy is to be given. TIP (Paclitaxel, Ifosfamide and cisplatin), VIP (Etoposide, Ifosfamide and cisplatin), VeIP (Vinpabline, Ifosfamide and cisplatin), Cisplatin/ Etoposide, Docetaxel/Carboplatin, Paclitaxel/Carboplatin, Paclitaxel/Gemcitabine, Paclitaxel/Ifosfamide, Paclitaxel, Docetaxel [14], Radiotherapy or supportive care is to be given. Referral of these patients to a tertiary care centre for stem cell transplant consultation and potentially curative therapy is strongly recommended. [14] Several case reports suggest these patients who have received chemotherapy for GCT may later present with growing teratoma syndrome. [19] In these patients consider either surgical resection or observe with monitoring. If fertility is not an issue, metastatic disease may be treated with radiation therapy because these tumors are extremely radiosensitive. Newer drugs like Olaparib, Palbociclib, Pembrolizumab, Avelumab, Durvalumab, Tremelimumab are molecular targeted therapy are under trial. [14]

5. Conclusion

Malignant GCT of ovary has an excellent prognosis if detected in early stage. High index of suspicion in young females presenting with ovarian mass and timely diagnosis and referral may result in high cure rates. The tumor marker level estimation plays a key role in the diagnosis, treatment and follow up of these patients. It is recommended that these patients should be treated by a tertiary care center where they will receive specialized care which has a direct impact on survival, quality of life and fertility preservation. The introduction of BEP chemotherapy regimen has made this disease curable. After appropriate treatment, 5 year survival is more than 85%. Survival after fertility preserving surgery is quite high and patients return to their reproductive functions shortly (3-4 months) after completing

| Author          | Total no. of patients in the study | Number of patients underwent fertility preservation surgery | No. of patients who became pregnant | Percentage |
|-----------------|-----------------------------------|-----------------------------------------------------------|------------------------------------|------------|
| Gershenson 1988 | 230                                | 40                                                        | 11                                 | 27.50      |
| Perrin 1999     | 45                                 | 45                                                        | 7                                  | 15.5       |
| Ezzat 1999      | 67                                 | 44                                                        | 16                                 | 36.36      |
| Brewer 1999     | 26                                 | 16                                                        | 5                                  | 31.25      |
| Lahshmanan 2018 | 39                                 | 14                                                        | 7                                  | 17.1       |
| Present Series  | 24                                 | 18                                                        | 1                                  | 5.55       |

For residual or recurrent disease high dose chemotherapy or additional chemotherapy is to be given. TIP (Paclitaxel, Ifosfamide and cisplatin), VIP (Etoposide, Ifosfamide and cisplatin), VeIP (Vinpabline, Ifosfamide and cisplatin), Cisplatin/ Etoposide, Docetaxel/Carboplatin, Paclitaxel/Carboplatin, Paclitaxel/Gemcitabine, Paclitaxel/Ifosfamide, Paclitaxel, Docetaxel [14], Radiotherapy or supportive care is to be given. Referral of these patients to a tertiary care centre for stem cell transplant consultation and potentially curative therapy is strongly recommended. [14] Several case reports suggest these patients who have received chemotherapy for GCT may later present with growing teratoma syndrome. [19] In these patients consider either surgical resection or observe with monitoring. If fertility is not an issue, metastatic disease may be treated with radiation therapy because these tumors are extremely radiosensitive. Newer drugs like Olaparib, Palbociclib, Pembrolizumab, Avelumab, Durvalumab, Tremelimumab are molecular targeted therapy are under trial. [14]
chemotherapy. BEP chemotherapy is effective first line chemotherapy regime and recurrence can be managed effectively with second line chemotherapy regimen. Women who retain one ovary might avoid sterility and premature ovarian failure and the attendant risk of accelerated cardiovascular disease and osteoporosis. Oocyte cryopreservation could be proposed to all adolescent patients and to all those who have not yet planned a pregnancy and a controlled ovarian hyperstimulation could also be considered after 12 months from chemotherapy treatment. Very little Indian studies had been published in literature. We hereby present rare cases of MOGCT at our institute.

Conflict of Interest

The authors declare that they have no competing interests.

References

[1] Stantorm BF and Behram RE, Overview of Pediatrics. In. Nelson Text Book of Pediatrics 17th Ed. Philadelphia: Saunders: 2011 pp1-13.
[2] Chen LH, Yip KC, Wu HJ and Yong SB. Yolk Sac Tumor in an Eight-Year Old Girl: A Case Report and Literature Review. Frontiers in Pediatrics 2019; 7: 169, doi: 10.3389/fped.2019.00169.
[3] Young JL Jr, Wu XC, Roffers SD, Howe HL, Correa C and Weinstein R. Ovarian Cancer in Children and young Adults in the United States 1992-1997. Cancer 2003 (S10) p 2694-2700.
[4] Tewari K, Cappuccini F, Disaia PJ, Berman ML, Manetta A, Kohler MF et al. Malignant ovarian tumors of the ovary. Obstet Gynecol 2000; 95: 128-133.
[5] Matei Daniela, Emerson R and Jubilee Brown. Ovarian Germ Cell Tumors Chapter 24, In: Principles and Practices of Gynecologic Oncology, 2017; 7th Edition by Dennis S Chi, Andrew Berchuck, Don S Dizon and Catheryn M Yashar. (Wolter Kluwer) pp. 708.
[6] Nogales FF, Dulcey I and Preda O. Germ Cell Tumors of the Ovary. An Update. Arch Pathol Lab Med 2014; 138: 351-362.
[7] Baker BA, Frickey L, Yu IT, Hawkins EP, Cushing B and Perlman EJ. DNA content of ovarian immature teratomas and malignant germ cell tumors. Gynecol Oncol 1998; 71 (1): 14-18.
[8] Gershenson DM, Copeland L J, Kavanagh JJ, Cangir A, Junco GD, Saul PB et al. Treatment of Malignant non dysgerminomatous germ cell tumors of the ovary with Vincristine, daunomycin and cyclophosphamide. Cancer 1985; 56 (12): 2756-2761.
[9] Rana AN, Humad H, Asif AM, Ghannam D and Nadeem N. Germ cell tumor presenting with Precocious Puberty in a Girl in United Arab Emirates. Dubai Medical Journal 2020; 3: 32-36.
[10] Mangili G, Sigismondi C, Gadducci A, Cormio G, Scollo P, Tateo S et al. Outcome and risk factors for recurrence in malignant ovarian germ cell tumors: A MITO-9 retrospective study. Int J Gynecol Cancer 2011, 21 (8): 1414-1421.
[11] Lakshmanan M, Gupta S, Kumar V, Akhtar N, Chaturvedi A, Mishra S et al. Germ Cell Tumor ovary: an institutional experience of treatment and survival outcomes. Indian J Sur Oncol 2018 Jun; 9(2): 215-219.
[12] Maheshwari A, Gupta S, Parikh PM and Tongaonkar HB. Malignant germ cell tumor ovary—experience at Tata Memorial Hospital. Indian J Med Pediatr Oncol 2004; 25(1): 43.
[13] Smith HO, Berwick M, Verschraegen CF, Wiggins C, Lansing L, Muller CY et al. Incidence and survival rates for female malignant germ cell tumors. Obstet Gynecol 2006; 107(5): 1075–1085.
[14] Giorgi UD, Casadei C, Bergamini A, Attademo L, Cormio G, Lorusso D et al. Therapeutic Challenges for Cisplatin-Resistant Ovarian Germ Cell Tumors. Cancers 2019; 11(10): 1584; https://doi.org/10.3390/cancers11101584.
[15] Gershenson DM. Menstrual and reproductive function after treatment with combination chemotherapy for malignant ovarian germ cell tumors. J Clin Oncol. 1988; 6 (2): 270-275.
[16] Perrin LC, Low J, Nicklin JL, Ward BG and Crandon AJ. Fertility and ovarian function after conservative surgery for germ cell tumors of the ovary. Aust N Z J Obstet Gynecol 1999; 39 (2): 243-244.
[17] Ezzat A, Raja M, Bakri Y, Subhi J, Memon M, Schwartz P et al. Malignant ovarian germ cell tumors: a survival and prognostic analysis. Acta Oncol. 1999; 38(4): 455–460.
[18] Brewer M, Gerhenson DM, Herzog CE, Mitchell MF, Silva EG and Wharton JT. Outcomes and reproductive function after chemotherapy for ovarian dysgerminoma. J Clin Oncol 1999; 17 (9): 2670–2675.
[19] Shibata K, Kajiyam H and Kikkawa F. Growing teratoma syndrome of the ovary showing three patterns of metastasis. A Case report. Case Rep Oncol 2013; 6: 544-549.